| 1 |
Sato Y, Okamoto K, Kida Y, Mitsui Y, Kawano Y, Sogabe M, Miyamoto H, Takayama T. Overview of Chemotherapy for Gastric Cancer. J Clin Med 2023;12. [PMID: 36835872 DOI: 10.3390/jcm12041336] [Reference Citation Analysis]
|
| 2 |
Yamasaki M, Sato Y, Okamoto K, Fukuya A, Kawaguchi T, Noda K, Kagemoto K, Mitsui Y, Miyamoto H, Takayama T. Two cases of anal squamous cell carcinoma achieving complete response after docetaxel + cisplatin + S-1 (DCS) induction chemotherapy followed by chemoradiation. Clin J Gastroenterol 2022. [DOI: 10.1007/s12328-022-01736-z] [Reference Citation Analysis]
|
| 3 |
Sato Y, Okamoto K, Kawaguchi T, Nakamura F, Miyamoto H, Takayama T. Treatment Response Predictors of Neoadjuvant Therapy for Locally Advanced Gastric Cancer: Current Status and Future Perspectives. Biomedicines 2022;10:1614. [DOI: 10.3390/biomedicines10071614] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 4 |
Hirahara N, Matsubara T, Kaji S, Yamamoto T, Hyakudomi R, Takai K, Ishitobi K, Uchida Y, Tajima Y. Phase II feasibility study of adjuvant chemotherapy with docetaxel/cisplatin/S-1 followed by S-1 for stage III gastric cancer. BMC Cancer 2021;21:1073. [PMID: 34598694 DOI: 10.1186/s12885-021-08795-4] [Reference Citation Analysis]
|
| 5 |
Tchounwou PB, Dasari S, Noubissi FK, Ray P, Kumar S. Advances in Our Understanding of the Molecular Mechanisms of Action of Cisplatin in Cancer Therapy. J Exp Pharmacol 2021;13:303-28. [PMID: 33776489 DOI: 10.2147/JEP.S267383] [Cited by in Crossref: 51] [Cited by in F6Publishing: 58] [Article Influence: 25.5] [Reference Citation Analysis]
|
| 6 |
Ohnuma H, Sato Y, Onoyama N, Hamaguchi K, Hayasaka N, Sato M, Murase K, Takada K, Miyanishi K, Murakami T, Ito T, Nobuoka T, Takemasa I, Kato J. Survival benefit of conversion surgery after intensive chemotherapy for unresectable metastatic gastric cancer: a propensity score-matching analysis. J Cancer Res Clin Oncol 2021;147:2385-96. [PMID: 33534051 DOI: 10.1007/s00432-021-03516-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 7 |
Hayashi T, Yoshikawa T, Sakamaki K, Nishikawa K, Fujitani K, Tanabe K, Misawa K, Matsui T, Miki A, Nemoto H, Fukunaga T, Kimura Y, Hihara J. Primary results of a randomized two-by-two factorial phase II trial comparing neoadjuvant chemotherapy with two and four courses of cisplatin/S-1 and docetaxel/cisplatin/S-1 as neoadjuvant chemotherapy for advanced gastric cancer. Ann Gastroenterol Surg 2020;4:540-8. [PMID: 33005849 DOI: 10.1002/ags3.12352] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 8 |
Nakagawa T, Sato Y, Tanahashi T, Mitsui Y, Kida Y, Fujino Y, Hirata M, Kitamura S, Miyamoto H, Okamoto K, Muguruma N, Bando Y, Takayama T. JMJD2A sensitizes gastric cancer to chemotherapy by cooperating with CCDC8. Gastric Cancer 2020;23:426-36. [PMID: 31677131 DOI: 10.1007/s10120-019-01024-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 9 |
Hosoda K, Azuma M, Katada C, Ishido K, Niihara M, Ushiku H, Sakuraya M, Washio M, Wada T, Watanabe A, Harada H, Tanabe S, Koizumi W, Yamashita K, Hiki N. A phase I study of docetaxel/oxaliplatin/S-1 (DOS) combination neoadjuvant chemotherapy for patients with locally advanced adenocarcinoma of the esophagogastric junction. Int J Clin Oncol 2020;25:1090-7. [PMID: 32124094 DOI: 10.1007/s10147-020-01638-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 10 |
Ohe Y, Fushida S, Yamaguchi T, Kinoshita J, Saito H, Okamoto K, Nakamura K, Tajima H, Ninomiya I, Ohta T. Peripheral Blood Platelet-Lymphocyte Ratio Is Good Predictor of Chemosensitivity and Prognosis in Gastric Cancer Patients. Cancer Manag Res 2020;12:1303-11. [PMID: 32110104 DOI: 10.2147/CMAR.S241069] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 11 |
Shekari N, Asghari F, Haghnavaz N, Shanehbandi D, Khaze V, Baradaran B, Kazemi T. Let-7a Could Serve as A Biomarker for Chemo-Responsiveness to Docetaxel in Gastric Cancer. Anticancer Agents Med Chem. 2019;19:304-309. [PMID: 30543177 DOI: 10.2174/1871520619666181213110258] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 12 |
Zhang F, Huang X, Song Y, Gao P, Zhou C, Guo Z, Shi J, Wu Z, Wang Z. Conversion Surgery for Stage IV Gastric Cancer. Front Oncol 2019;9:1158. [PMID: 31788445 DOI: 10.3389/fonc.2019.01158] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 13 |
Yamada Y, Boku N, Mizusawa J, Iwasa S, Kadowaki S, Nakayama N, Azuma M, Sakamoto T, Shitara K, Tamura T, Chin K, Hata H, Nakamori M, Hara H, Yasui H, Katayama H, Fukuda H, Yoshikawa T, Sasako M, Terashima M. Docetaxel plus cisplatin and S-1 versus cisplatin and S-1 in patients with advanced gastric cancer (JCOG1013): an open-label, phase 3, randomised controlled trial. Lancet Gastroenterol Hepatol 2019;4:501-10. [PMID: 31101534 DOI: 10.1016/S2468-1253(19)30083-4] [Cited by in Crossref: 55] [Cited by in F6Publishing: 63] [Article Influence: 13.8] [Reference Citation Analysis]
|
| 14 |
Okabe H, Hata H, Hosogi H, Ueda S, Ota S, Kinjo Y, Hoshino N, Hisamori S, Tsunoda S, Obama K, Sakai Y; The Kyoto University Surgical Oncology Group (KUSOG). A Phase 2 Study of Induction Chemotherapy Using Docetaxel, Cisplatin, and S-1 for Gastric Cancer with Peritoneal Metastasis (KUGC06). Ann Surg Oncol 2019;26:1779-86. [DOI: 10.1245/s10434-019-07229-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 15 |
Du R, Hu P, Liu Q, Zhang J. Conversion Surgery for Unresectable Advanced Gastric Cancer: A Systematic Review and Meta-Analysis. Cancer Invest 2019;37:16-28. [PMID: 30632817 DOI: 10.1080/07357907.2018.1551898] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 16 |
Nie R, Yuan S, Li Y, Chen S, Li S, Yang L, Yang L, Chen Y, Zhou Z. Risk-stratification model to select conversion surgery for advanced gastric cancer patients. Chin J Cancer Res 2019;31:178-87. [PMID: 30996576 DOI: 10.21147/j.issn.1000-9604.2019.01.13] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 17 |
Shinkai M, Imano M, Chiba Y, Iwama M, Shiraisi O, Yasuda A, Tsubaki M, Nishida S, Kimura Y, Yasuda T. Phase II trial of neoadjuvant chemotherapy with intraperitoneal paclitaxel, S-1, and intravenous cisplatin and paclitaxel for stage IIIA or IIIB gastric cancer. J Surg Oncol 2019;119:56-63. [PMID: 30444009 DOI: 10.1002/jso.25295] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 18 |
Sato Y, Sagawa T, Ohnuma H, Hirakawa M, Takahashi Y, Hamaguchi K, Fujikawa K, Nobuoka T, Okamoto K, Miyamoto H, Muguruma N, Takemasa I, Takayama T. A dose-escalation study of docetaxel, oxaliplatin, and S-1 (DOS) as a first-line therapy for patients with unresectable metastatic gastric cancer. Cancer Chemother Pharmacol 2019;83:161-7. [PMID: 30406285 DOI: 10.1007/s00280-018-3719-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 19 |
Aoyama T, Nishikawa K, Fujitani K, Tanabe K, Ito S, Matsui T, Miki A, Nemoto H, Sakamaki K, Fukunaga T, Kimura Y, Hirabayashi N, Yoshikawa T. Early results of a randomized two-by-two factorial phase II trial comparing neoadjuvant chemotherapy with two and four courses of cisplatin/S-1 and docetaxel/cisplatin/S-1 as neoadjuvant chemotherapy for locally advanced gastric cancer. Ann Oncol 2017;28:1876-81. [PMID: 28486692 DOI: 10.1093/annonc/mdx236] [Cited by in Crossref: 34] [Cited by in F6Publishing: 40] [Article Influence: 6.8] [Reference Citation Analysis]
|
| 20 |
Fujimoto D, Goi T, Koneri K, Hirono Y. RPN2 is effective biomarker to predict the outcome of combined chemotherapy docetaxel and cisplatin for advanced gastric cancer. Oncotarget 2018;9:15208-18. [PMID: 29632637 DOI: 10.18632/oncotarget.24622] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 21 |
Ohnuma H, Sato Y, Hirakawa M, Kikuchi S, Miyanishi K, Sagawa T, Takahashi Y, Nobuoka T, Okamoto K, Miyamoto H, Takemasa I, Takayama T, Kato J. Docetaxel, cisplatin and S-1 (DCS) combination chemotherapy for gastric cancer patients with peritoneal metastasis: a retrospective study. Cancer Chemother Pharmacol. 2018;81:539-548. [PMID: 29383482 DOI: 10.1007/s00280-018-3523-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 22 |
Kagawa S, Muraoka A, Kambara T, Nakayama H, Hamano R, Tanaka N, Noma K, Tanakaya K, Kishimoto H, Shigeyasu K, Kuroda S, Kikuchi S, Kuwada K, Nishizaki M, Shirakawa Y, Fujiwara T. A multi-institution phase II study of docetaxel and S-1 in combination with trastuzumab for HER2-positive advanced gastric cancer (DASH study). Cancer Chemother Pharmacol 2018;81:387-92. [PMID: 29290024 DOI: 10.1007/s00280-017-3505-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 23 |
Hosokawa A, Ando T, Ogawa K, Ueda A, Yoshita H, Mihara H, Fujinami H, Kajiura S, Yabushita K, Horikawa N, Kobayashi Y, Yoshioka A, Origasa H, Sugiyama T. Phase I/II Study of S-1 Plus Cisplatin Alternating With S-1 Plus Docetaxel in Patients With Advanced Gastric Cancer. Am J Clin Oncol 2018;41:977-81. [PMID: 28930775 DOI: 10.1097/COC.0000000000000405] [Reference Citation Analysis]
|
| 24 |
Uemura N, Kikuchi S, Sato Y, Ohnuma H, Okamoto K, Miyamoto H, Hirakawa M, Sagawa T, Fujikawa K, Takahashi Y, Okuda T, Minami S, Takahashi M, Okamoto T, Takada K, Miyanisi K, Takayama T, Kato J. A phase II study of modified docetaxel, cisplatin, and S-1 (mDCS) chemotherapy for unresectable advanced gastric cancer. Cancer Chemother Pharmacol 2017;80:707-13. [PMID: 28849257 DOI: 10.1007/s00280-017-3404-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 25 |
Sasaki K, Onodera S, Otsuka K, Satomura H, Kurayama E, Kubo T, Takahashi M, Ito J, Nakajima M, Yamaguchi S, Miyachi K, Kato H. Validity of neoadjuvant chemotherapy with docetaxel, cisplatin, and S-1 for resectable locally advanced gastric cancer. Med Oncol 2017;34:139. [PMID: 28707042 DOI: 10.1007/s12032-017-0997-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 26 |
Sato Y, Ohnuma H, Nobuoka T, Hirakawa M, Sagawa T, Fujikawa K, Takahashi Y, Shinya M, Katsuki S, Takahashi M, Maeda M, Okagawa Y, Naoki U, Kikuch S, Okamoto K, Miyamoto H, Shimada M, Takemasa I, Kato J, Takayama T. Conversion therapy for inoperable advanced gastric cancer patients by docetaxel, cisplatin, and S-1 (DCS) chemotherapy: a multi-institutional retrospective study. Gastric Cancer 2017;20:517-26. [PMID: 27553665 DOI: 10.1007/s10120-016-0633-1] [Cited by in Crossref: 44] [Cited by in F6Publishing: 54] [Article Influence: 7.3] [Reference Citation Analysis]
|
| 27 |
Saito H, Fushida S, Miyashita T, Oyama K, Yamaguchi T, Tsukada T, Kinoshita J, Tajima H, Ninomiya I, Ohta T. Potential of extravasated platelet aggregation as a surrogate marker for overall survival in patients with advanced gastric cancer treated with preoperative docetaxel, cisplatin and S-1: a retrospective observational study. BMC Cancer. 2017;17:294. [PMID: 28449652 DOI: 10.1186/s12885-017-3279-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 28 |
Yuan M, Shi Z, Wang Z, Lv W, Yang Y, Lu F, Zhao Y, Zhong H. The significance of multi-line chemotherapy for advanced gastric cancer: A retrospective analysis. Mol Clin Oncol 2017;6:606-12. [PMID: 28413678 DOI: 10.3892/mco.2017.1163] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 29 |
Ito S, Sano T, Mizusawa J, Takahari D, Katayama H, Katai H, Kawashima Y, Kinoshita T, Terashima M, Nashimoto A, Nakamori M, Onaya H, Sasako M. A phase II study of preoperative chemotherapy with docetaxel, cisplatin, and S-1 followed by gastrectomy with D2 plus para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis: JCOG1002. Gastric Cancer 2017;20:322-31. [PMID: 27299887 DOI: 10.1007/s10120-016-0619-z] [Cited by in Crossref: 71] [Cited by in F6Publishing: 75] [Article Influence: 11.8] [Reference Citation Analysis]
|
| 30 |
Maeda O, Matsuoka A, Miyahara R, Funasaka K, Hirooka Y, Fukaya M, Nagino M, Kodera Y, Goto H, Ando Y. Modified docetaxel, cisplatin and capecitabine for stage IV gastric cancer in Japanese patients: A feasibility study. World J Gastroenterol 2017; 23(6): 1090-1097 [PMID: 28246483 DOI: 10.3748/wjg.v23.i6.1090] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 31 |
Kubo T, Kawano Y, Himuro N, Sugita S, Sato Y, Ishikawa K, Takada K, Murase K, Miyanishi K, Sato T, Takimoto R, Kobune M, Nobuoka T, Hirata K, Takayama T, Mori M, Hasegawa T, Kato J. BAK is a predictive and prognostic biomarker for the therapeutic effect of docetaxel treatment in patients with advanced gastric cancer. Gastric Cancer 2016;19:827-38. [PMID: 26486506 DOI: 10.1007/s10120-015-0557-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 32 |
Kang BW, Kwon OK, Chung HY, Yu W, Kim JG. Taxanes in the Treatment of Advanced Gastric Cancer. Molecules. 2016;21:pii: E651. [PMID: 27196887 DOI: 10.3390/molecules21050651] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 33 |
Yoshida K, Yamaguchi K, Okumura N, Tanahashi T, Kodera Y. Is conversion therapy possible in stage IV gastric cancer: the proposal of new biological categories of classification. Gastric Cancer 2016;19:329-38. [PMID: 26643880 DOI: 10.1007/s10120-015-0575-z] [Cited by in Crossref: 166] [Cited by in F6Publishing: 178] [Article Influence: 23.7] [Reference Citation Analysis]
|
| 34 |
Ito S, Ito Y, Misawa K, Shimizu Y, Kinoshita T. Neoadjuvant chemotherapy followed by surgery in gastric cancer patients with extensive lymph node metastasis. World J Clin Oncol 2015; 6(6): 291-294 [PMID: 26677442 DOI: 10.5306/wjco.v6.i6.291] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 35 |
Miyoshi J, Miyamoto H, Goji T, Taniguchi T, Tomonari T, Sogabe M, Kimura T, Kitamura S, Okamoto K, Fujino Y, Muguruma N, Okahisa T, Takayama T. Serum diamine oxidase activity as a predictor of gastrointestinal toxicity and malnutrition due to anticancer drugs. J Gastroenterol Hepatol 2015;30:1582-90. [PMID: 25968084 DOI: 10.1111/jgh.13004] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 36 |
Mitsui Y, Sato Y, Miyamoto H, Fujino Y, Takaoka T, Miyoshi J, Kagawa M, Ohnuma H, Hirakawa M, Kubo T. Trastuzumab in combination with docetaxel/cisplatin/S-1 (DCS) for patients with HER2-positive metastatic gastric cancer: feasibility and preliminary efficacy. Cancer Chemother Pharmacol. 2015;76:375-382. [PMID: 26099968 DOI: 10.1007/s00280-015-2807-7] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 37 |
Migita K, Nashimoto A, Yabusaki H, Matsuki A, Aizawa M. Efficacy of neoadjuvant chemotherapy with docetaxel, cisplatin and S-1 for resectable locally advanced gastric cancer. Int J Clin Oncol 2016;21:102-9. [DOI: 10.1007/s10147-015-0851-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 38 |
Kinoshita J, Fushida S, Tsukada T, Oyama K, Okamoto K, Makino I, Nakamura K, Miyashita T, Tajima H, Takamura H, Ninomiya I, Ohta T. Efficacy of conversion gastrectomy following docetaxel, cisplatin, and S-1 therapy in potentially resectable stage IV gastric cancer. Eur J Surg Oncol 2015;41:1354-60. [PMID: 26028256 DOI: 10.1016/j.ejso.2015.04.021] [Cited by in Crossref: 35] [Cited by in F6Publishing: 46] [Article Influence: 4.4] [Reference Citation Analysis]
|
| 39 |
Nishino H, Sasaki B, Asao Y, Furuyama H, Yoshimura T. A Long Surviving Case of Gastric Cancer with Liver Metastasis and Portal Vein Thrombus Successfully Treated by Surgical Resection after S-1 and CDDP Chemotherapy. Jpn J Gastroenterol Surg, Nihon Shokaki Geka Gakkai zasshi 2015;48:297-305. [DOI: 10.5833/jjgs.2014.0065] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 40 |
Yang J, Zhou Y, Min K, Yao Q, Xu CN. S-1-based vs non-S-1-based chemotherapy in advanced gastric cancer: A meta-analysis. World J Gastroenterol 2014; 20(33): 11886-11893 [PMID: 25206296 DOI: 10.3748/wjg.v20.i33.11886] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 41 |
Ina K, Kataoka T, Ando T. The use of lentinan for treating gastric cancer. Anticancer Agents Med Chem 2013;13:681-8. [PMID: 23092289 DOI: 10.2174/1871520611313050002] [Cited by in Crossref: 129] [Cited by in F6Publishing: 138] [Article Influence: 14.3] [Reference Citation Analysis]
|
| 42 |
Xu AM, Huang L, Liu W, Gao S, Han WX, Wei ZJ. Neoadjuvant chemotherapy followed by surgery versus surgery alone for gastric carcinoma: systematic review and meta-analysis of randomized controlled trials. PLoS One. 2014;9:e86941. [PMID: 24497999 DOI: 10.1371/journal.pone.0086941] [Cited by in Crossref: 48] [Cited by in F6Publishing: 57] [Article Influence: 5.3] [Reference Citation Analysis]
|
| 43 |
Xu AM, Huang L, Liu W, Gao S, Han WX, Wei ZJ. Neoadjuvant chemotherapy followed by surgery versus surgery alone for gastric carcinoma: systematic review and meta-analysis of randomized controlled trials. PLoS One. 2014;9:e86941. [PMID: 24497999 DOI: 10.1371/journal.pone.0086941.ecollection] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 44 |
Fushida S, Oyama K, Kinoshita J, Yagi Y, Okamoto K, Tajima H, Ninomiya I, Fujimura T, Ohta T. VEGF is a target molecule for peritoneal metastasis and malignant ascites in gastric cancer: prognostic significance of VEGF in ascites and efficacy of anti-VEGF monoclonal antibody. Onco Targets Ther. 2013;6:1445-1451. [PMID: 24204159 DOI: 10.2147/ott.s51916] [Cited by in Crossref: 27] [Cited by in F6Publishing: 34] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 45 |
Yang J, Zhou Y, Chen JF. Role of S-1 in treatment of advanced gastric cancer. Shijie Huaren Xiaohua Zazhi 2013; 21(28): 2950-2956 [DOI: 10.11569/wcjd.v21.i28.2950] [Reference Citation Analysis]
|
| 46 |
Shiraishi K, Mimura K, Izawa S, Inoue A, Shiba S, Maruyama T, Watanabe M, Kawaguchi Y, Inoue M, Fujii H, Kono K. Lapatinib acts on gastric cancer through both antiproliferative function and augmentation of trastuzumab-mediated antibody-dependent cellular cytotoxicity. Gastric Cancer 2013;16:571-80. [PMID: 23187882 DOI: 10.1007/s10120-012-0219-5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 47 |
Chen XL, Chen XZ, Yang C, Liao YB, Li H, Wang L, Yang K, Li K, Hu JK, Zhang B, Chen ZX, Chen JP, Zhou ZG. Docetaxel, cisplatin and fluorouracil (DCF) regimen compared with non-taxane-containing palliative chemotherapy for gastric carcinoma: a systematic review and meta-analysis. PLoS One. 2013;8:e60320. [PMID: 23593191 DOI: 10.1371/journal.pone.0060320] [Cited by in Crossref: 29] [Cited by in F6Publishing: 36] [Article Influence: 2.9] [Reference Citation Analysis]
|
| 48 |
Hirakawa M, Sato Y, Ohnuma H, Takayama T, Sagawa T, Nobuoka T, Harada K, Miyamoto H, Sato Y, Takahashi Y. A phase II study of neoadjuvant combination chemotherapy with docetaxel, cisplatin, and S-1 for locally advanced resectable gastric cancer: nucleotide excision repair (NER) as potential chemoresistance marker. Cancer Chemother Pharmacol. 2013;71:789-797. [PMID: 23338051 DOI: 10.1007/s00280-013-2073-5] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 4.2] [Reference Citation Analysis]
|
| 49 |
Kimura Y, Yano H, Imamura H, Fujitani K, Imano M, Tokunaga Y, Matsuoka M, Kurokawa Y, Shimokawa T, Takiuchi H, Tsujinaka T, Furukawa H. A phase I study of triplet combination chemotherapy of paclitaxel, cisplatin and S-1 in patients with advanced gastric cancer. Jpn J Clin Oncol 2013;43:125-31. [PMID: 23225911 DOI: 10.1093/jjco/hys204] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 50 |
Tada Y, Maruya SI, Saotome T, Miura K, Masubuchi T, Fushimi C, Okamoto I, Takeishi E, Yamada S, Asai H, Kamata SE. Phase I/II study of docetaxel, cisplatin and S-1 in locally advanced, recurrent and metastatic head and neck squamous cell carcinoma. Oncol Lett 2012;4:898-904. [PMID: 23162619 DOI: 10.3892/ol.2012.846] [Reference Citation Analysis]
|
| 51 |
Cui Y, Li Q, Yu Y, Chen Y, Feng Y, Wang Y, Liu T. Combination of low-dose docetaxel and standard-dose S-1 for the treatment of advanced gastric cancer: efficacy, toxicity, and potential predictive factor. Cancer Chemother Pharmacol 2013;71:145-52. [PMID: 23064955 DOI: 10.1007/s00280-012-1991-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 52 |
Satoh T, Sakata Y. S-1 for the treatment of gastrointestinal cancer. Expert Opin Pharmacother 2012;13:1943-59. [PMID: 22860709 DOI: 10.1517/14656566.2012.709234] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 53 |
Hasegawa H, Fujitani K, Nakazuru S, Hirao M, Mita E, Tsujinaka T. Optimal indications for second-line chemotherapy in advanced gastric cancer. Anticancer Drugs. 2012;23:465-470. [PMID: 22227714 DOI: 10.1097/cad.0b013e3283504442] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 54 |
Katayama H, Ito S, Sano T, Takahari D, Mizusawa J, Boku N, Tsuburaya A, Terashima M, Sasako M; Stomach Cancer Study Group of the Japan Clinical Oncology Group. A Phase II study of systemic chemotherapy with docetaxel, cisplatin, and S-1 (DCS) followed by surgery in gastric cancer patients with extensive lymph node metastasis: Japan Clinical Oncology Group study JCOG1002. Jpn J Clin Oncol 2012;42:556-9. [PMID: 22525210 DOI: 10.1093/jjco/hys054] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 55 |
Sato T, Rino Y, Yamada R, Oshima T, Masuda M. Neoadjuvant Chemotherapy of Resectable Advanced Gastric Cancer. JJCS 2012;37:197-204. [DOI: 10.4030/jjcs.37.197] [Reference Citation Analysis]
|
| 56 |
Yoshikawa T, Kuwabara H, Aoyama T, Mikayama Y, Hayashi T, Ogata T, Cho H, Tsuburaya A, Morita T, Sakamoto J. Future Development of Adjuvant Chemotherapy for Gastric Cancer. JJCS 2012;37:686-690. [DOI: 10.4030/jjcs.37.686] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 57 |
Yamasaki Y, Fushida S, Oyama K, Kinoshita J, Makino I, Nakamura K, Fujita H, Ninomiya I, Fujimura T, Ohta T. A Case of Advanced Gastric Cancer Responding to Neoadjuvant Chemotherapy. Jpn J Gastroenterol Surg 2012;45:258-266. [DOI: 10.5833/jjgs.45.258] [Reference Citation Analysis]
|
| 58 |
Fujitani K, Mano M, Hirao M, Kodama Y, Tsujinaka T. Posttherapy nodal status, not graded histologic response, predicts survival after neoadjuvant chemotherapy for advanced gastric cancer. Ann Surg Oncol 2012;19:1936-43. [PMID: 22187120 DOI: 10.1245/s10434-011-2165-6] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 59 |
Inoue K, Nakane Y, Kogire M, Fujitani K, Kimura Y, Imamura H, Tamura S, Okano S, Kwon AH, Kurokawa Y, Shimokawa T, Takiuchi H, Tsujinaka T, Furukawa H. Phase II trial of preoperative S-1 plus cisplatin followed by surgery for initially unresectable locally advanced gastric cancer. Eur J Surg Oncol 2012;38:143-9. [PMID: 22154885 DOI: 10.1016/j.ejso.2011.11.009] [Cited by in Crossref: 22] [Cited by in F6Publishing: 30] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 60 |
Yoshikawa T, Taguri M, Sakuramoto S, Kunisaki C, Fukunaga T, Ito S, Cho H, Tanabe K, Nishikawa K, Matsui T. A comparison of multimodality treatment: two and four courses of neoadjuvant chemotherapy using S-1/CDDP or S-1/CDDP/docetaxel followed by surgery and S-1 adjuvant chemotherapy for macroscopically resectable serosa-positive gastric cancer: a randomized phase II trial (COMPASS-D trial). Jpn J Clin Oncol. 2012;42:74-77. [PMID: 22102736 DOI: 10.1093/jjco/hyr166] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 61 |
Oyama K, Fushida S, Kinoshita J, Makino I, Nakamura K, Hayashi H, Nakagawara H, Tajima H, Fujita H, Takamura H, Ninomiya I, Kitagawa H, Tani T, Fujimura T, Ohta T. Efficacy of pre-operative chemotherapy with docetaxel, cisplatin, and S-1 (DCS therapy) and curative resection for gastric cancer with pathologically positive para-aortic lymph nodes. J Surg Oncol. 2012;105:535-541. [PMID: 22006649 DOI: 10.1002/jso.22125] [Cited by in Crossref: 29] [Cited by in F6Publishing: 36] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 62 |
Ina K, Furuta R, Kataoka T, Kayukawa S, Yoshida T, Miwa T, Yamamura Y, Takeuchi Y. Lentinan prolonged survival in patients with gastric cancer receiving S-1-based chemotherapy. World J Clin Oncol 2011; 2(10): 339-343 [PMID: 21994907 DOI: 10.5306/wjco.v2.i10.339] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 39] [Article Influence: 3.1] [Reference Citation Analysis]
|
| 63 |
Koizumi W, Nakayama N, Tanabe S, Sasaki T, Higuchi K, Nishimura K, Takagi S, Azuma M, Ae T, Ishido K, Nakatani K, Naruke A, Katada C. A multicenter phase II study of combined chemotherapy with docetaxel, cisplatin, and S-1 in patients with unresectable or recurrent gastric cancer (KDOG 0601). Cancer Chemother Pharmacol. 2012;69:407-413. [PMID: 21796483 DOI: 10.1007/s00280-011-1701-1] [Cited by in Crossref: 57] [Cited by in F6Publishing: 63] [Article Influence: 4.8] [Reference Citation Analysis]
|
| 64 |
Hashimoto I, Nashimoto A, Yabusaki H, Nakagawa S, Matsuki A. A Case of Advanced Gastric Cancer with Abdominal Paraaortic and Virchow's Lymph Node Metastasis Responding to Pathological CR After Preoperative Combined Docetaxel, Cisplatin, and S^|^ndash;1 Chemotherapy. JJCS 2011;36:796-801. [DOI: 10.4030/jjcs.36.796] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 65 |
Higuchi K, Tanabe S, Azuma M, Sasaki T, Ishido K, Koizumi W. Future Perspectives for the Development of Chemotherapy for Advanced Gastric Cancer: Japanese and Global Status. Pathobiology 2011;78:334-42. [DOI: 10.1159/000321700] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
